Adaptive Biotechnologies Corporation (ADPT)
Last updated: 2026-11-19 02:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Adaptive Biotechnologies Corporation (ADPT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $28.44, with a market capitalization of $4.51B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.00 to $32.21. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$4.51B | |
$27.79 | |
$29.20 | |
$27.79 | |
$28.49 | |
1.93M | |
2.19M | |
-- | |
$32.21 | |
$12.00 | |
-- | |
2026-09-30 |
Adaptive Biotechnologies Corporation (ADPT) Latest Closing Stock Price
Adaptive Biotechnologies Corporation (ADPT) last closed at $28.44 as of 2026-11-19 00:31:00, down 0.14% ($0.04) from the previous close of $28.49.
During the latest regular trading session, ADPT traded between $27.79 and $29.20, with a volume of 1.93M shares. The closing price was near the middle and near the upper end of its 52-week range.
Adaptive Biotechnologies Corporation (ADPT) 7-Day Stock Price Change
Over the past seven days, Adaptive Biotechnologies Corporation (ADPT) moved from $30.26 to $28.44, representing a decline of 6.01% ($1.82).
The stock traded between $27.29 and $32.21 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.27 million shares, down versus the previous seven-day period, indicating lower trading activity.
ADPT 52-Week Price Position
Position in Range: 81.3%
ADPT is currently trading at $28.44, placing it 81.3% of the way from its 52-week low of $12.00 to its 52-week high of $32.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Adaptive Biotechnologies Corporation (ADPT)?
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Adaptive Biotechnologies Corporation Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 624 |
| Exchange | NASDAQ |
| Company Website |
ADPT News
Latest news related to Adaptive Biotechnologies Corporation and ADPT stock.
- Read Full Article
- Read Full Article
Here's Why You Should Add AURA Stock to Your Portfolio Now
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
- Read Full Article
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
- Read Full Article
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.
Ways to Trade ADPT at MEXC
How to Buy Adaptive Biotechnologies Corporation (ADPT) Stock on MEXC
Eligible investors can buy real shares of Adaptive Biotechnologies Corporation (ADPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Adaptive Biotechnologies Corporation (ADPT) stock price today?
2.Is ADPT stock going up or down today?
3.What is ADPT pre-market price?
4.What is ADPT after-hours price?
5.Is ADPT stock trading now?
6.Where does ADPT sit relative to its 52-week high and low?
7.What sector is Adaptive Biotechnologies Corporation in?
8.What is Adaptive Biotechnologies Corporation's market capitalization and where is it listed?
9.How is ADPT valued in terms of P/E ratio and EPS?
10.Does Adaptive Biotechnologies Corporation pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ADPT, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
ADPT Stock Calculator
Estimate the value between ADPT shares and USD.
ADPT Shares to USD
1.00 ADPT shares = 28.44 USD
Calculations are estimates based on the latest available price and are for reference only.


